Role of Eosinophil in Fibrogenesis of Systemic Sclerosis

UnknownOBSERVATIONAL
Enrollment

65

Participants

Timeline

Start Date

October 3, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Systemic SclerosisSystemic Scleroderma
Interventions
DIAGNOSTIC_TEST

Blood test

Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing

DIAGNOSTIC_TEST

Skin biopsies

In patients who will accept, skin biopsies will be performed in damaged and apparently normal skin, excluding fingers, hands, feet and face (biopsies are facultative)

Trial Locations (1)

Unknown

Hôpital Claude Huriez, CHU, Lille

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University Hospital, Lille

OTHER

NCT03816189 - Role of Eosinophil in Fibrogenesis of Systemic Sclerosis | Biotech Hunter | Biotech Hunter